Stephan Moll, MD writes…. Today (Jan 8th, 2015) the FDA approved yet another new oral blood thinner, Savaysa (edoxaban), for the treatment of DVT and PE. The drug was also FDA approved today for stroke prevention in patients with irregular heart beat (atrial fibrillation). The FDA press release here (link).
Savaysa is the 4th drug of the group of oral blood thinners that all do not require routine monitoring of its blood thinning effect (referred to as NOACs = new oral anticoagulants); the other three are Xarelto (rivaroxaban), Eliquis (apixaban) and Pradaxa (dabigatran). This table summarizes the differences, advantages and disadvantages comparing the 4 drugs for the treatment of DVT and PE. The detailed drug package insert with dosing information is here (link).
For the management of acute DVT and PE, Savaysa has the disadvantage compared to Xarelto and Eliquis that it should not be used immediately when the diagnosis of a blood clot is made, but only after 5-10 days of treatment with another blood thinner (such as an injectable low molecular weight heparin). That makes treatment of acute DVT and PE with Savaysa more cumbersome than with Xarelto or Eliquis.
Disclosures: I have consulted in the past for Daiichi, Janssen and Boehringer-Ingelheim.
Last updated: Jan 9th, 2015